BRPI0722060A2 - Inibição mediada por shrna de expressão de alfa-1,6-fucosiltransferase - Google Patents

Inibição mediada por shrna de expressão de alfa-1,6-fucosiltransferase

Info

Publication number
BRPI0722060A2
BRPI0722060A2 BRPI0722060-0A2A BRPI0722060A BRPI0722060A2 BR PI0722060 A2 BRPI0722060 A2 BR PI0722060A2 BR PI0722060 A BRPI0722060 A BR PI0722060A BR PI0722060 A2 BRPI0722060 A2 BR PI0722060A2
Authority
BR
Brazil
Prior art keywords
fucosiltransferase
shrna
alpha
expression
mediated inhibition
Prior art date
Application number
BRPI0722060-0A2A
Other languages
English (en)
Inventor
Vincent Beuger
Helmut Burtscher
Christian Klein
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0722060A2 publication Critical patent/BRPI0722060A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01068—Glycoprotein 6-alpha-L-fucosyltransferase (2.4.1.68), i.e. FUT8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
BRPI0722060-0A2A 2006-12-22 2007-12-19 Inibição mediada por shrna de expressão de alfa-1,6-fucosiltransferase BRPI0722060A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06026653 2006-12-22
PCT/EP2007/011160 WO2008077547A1 (en) 2006-12-22 2007-12-19 Shrna-mediated inhibition of expression of alpha-1. 6-fucosyltransferase

Publications (1)

Publication Number Publication Date
BRPI0722060A2 true BRPI0722060A2 (pt) 2014-04-01

Family

ID=37890199

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0722060-0A2A BRPI0722060A2 (pt) 2006-12-22 2007-12-19 Inibição mediada por shrna de expressão de alfa-1,6-fucosiltransferase

Country Status (11)

Country Link
US (2) US20100028949A1 (pt)
EP (1) EP2097445A1 (pt)
JP (1) JP2010512766A (pt)
KR (1) KR101114741B1 (pt)
CN (1) CN101553503B (pt)
AU (1) AU2007338403B2 (pt)
BR (1) BRPI0722060A2 (pt)
CA (1) CA2672980A1 (pt)
IL (1) IL197929A (pt)
MX (1) MX2009006336A (pt)
WO (1) WO2008077547A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8249332B2 (en) 2008-05-22 2012-08-21 Matrix Electronic Measuring Properties Llc Stereoscopic measurement system and method
US8326022B2 (en) 2008-05-22 2012-12-04 Matrix Electronic Measuring Properties, Llc Stereoscopic measurement system and method
US8345953B2 (en) 2008-05-22 2013-01-01 Matrix Electronic Measuring Properties, Llc Stereoscopic measurement system and method
US9449378B2 (en) 2008-05-22 2016-09-20 Matrix Electronic Measuring Properties, Llc System and method for processing stereoscopic vehicle information
FR2956122A1 (fr) * 2010-02-08 2011-08-12 Lfb Biotechnologies Utilisation d'un represseur d'un gene codant une enzyme possedant une activite glycosyltrasferase
EP3042952A1 (en) 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
US20180238974A1 (en) * 2017-02-17 2018-08-23 QuSpin Inc. Gradient Field Optically Pumped Magnetometer
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) * 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
CN112513623B (zh) * 2018-07-20 2023-03-28 Npl管理有限公司 用于检测物质响应的方法和系统
US20220002387A1 (en) * 2018-11-06 2022-01-06 University Of Miami Compositions and Production of Recombinant AAV Viral Vectors Capable of Glycoengineering In Vivo
EP3941480A4 (en) * 2019-03-18 2023-04-26 Score Pharma, Inc. FUCOSYLATION INHIBITION COMPOUNDS AND METHODS OF USE THEREOF

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US20040132140A1 (en) * 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
CN102911987B (zh) * 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
US20070134759A1 (en) * 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
EP1888638A2 (en) * 2005-06-03 2008-02-20 Genentech, Inc. Method of producing antibodies with modified fucosylation level

Also Published As

Publication number Publication date
US20110151513A1 (en) 2011-06-23
KR101114741B1 (ko) 2012-02-29
AU2007338403B2 (en) 2012-09-06
AU2007338403A1 (en) 2008-07-03
EP2097445A1 (en) 2009-09-09
KR20090106481A (ko) 2009-10-09
IL197929A (en) 2013-06-27
CN101553503A (zh) 2009-10-07
CN101553503B (zh) 2012-11-07
IL197929A0 (en) 2011-08-01
JP2010512766A (ja) 2010-04-30
CA2672980A1 (en) 2008-07-03
US20100028949A1 (en) 2010-02-04
WO2008077547A1 (en) 2008-07-03
MX2009006336A (es) 2009-06-23

Similar Documents

Publication Publication Date Title
BRPI0722060A2 (pt) Inibição mediada por shrna de expressão de alfa-1,6-fucosiltransferase
CR10851A (es) Inhibidores de la actividad de la akt
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
BRPI0807146A2 (pt) Inibidores da atividade da akt
BRPI0718313A2 (pt) Conjunto de cateter
EP2092892A4 (en) ULTRASOUND DEVICE
IL202366A0 (en) RNAi INHIBITION OF ALPHA-ENAC EXPRESSION
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
CR10478A (es) Amino-piperidine derivatives as cetp inhibitors
AU310576S (en) Sanitary napkin
AU310577S (en) Sanitary napkin
BRPI0909422A2 (pt) conjunto de artigos.
LU93092I2 (de) Alemtuzumab
DE102006026707A8 (de) Duschwanne
BR112012003115A2 (pt) agente de pós-clarificação
DE502007004416D1 (de) Avermectinderivate
ITVR20060037A1 (it) Tovagliolo, particolarmente per sommelier
TH99520B (th) ผ้าอนามัย
HK1141311A (en) Rnai inhibition of alpha-enac expression
TH102575B (th) ผ้าอนามัย
CR10502S (es) Toalla sanitaria / protector diario
ES1063288Y (es) Dispensador de ceniceros
ITRG20080001U1 (it) Vassoio - organizer per piatto, bicchiere, posate e tovagliolo usa e getta.
ZA200908301B (en) Rnai inhibition of alpha-enac expression
UA13643S (uk) Упаковка для серветок

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2285 DE 21/10/2014.